Ottobock SE & Co. KGaA

  Duderstadt, 21 August 2025 Successful implementation of the growth strategy with strategic product launches and numerous acquisitions; significant improvement in EBITDA margins through economies of scale and efficiency gains Revenue increased to EUR 801 million (H1 2024: EUR 763 million), up 5.0% (organic growth: 10.0%) Underlying EBITDA increased by 30.5% to EUR 180 million (H1 2024: EUR 138 million); underlying EBITDA margin of 22.5% (H1 2024: 18.1%)   Ottobock, the global MedTech champion and international market leader in Human Bionics, continued its growth trajectory in the first half of 2025. The company recorded a 5.0% increase in revenue to EUR 801 million in the first six months of the year (H1 2024: EUR 763 million), with organic growth of 10.0%. Strategic product launches and seven successful acquisitions significantly contributed to this positive development. At the same time, underlying EBITDA increased by 30.5% to EUR 180 million (H1 2024: EUR 138 million). This was mainly due to a favorable product mix, economies of scale, and operational efficiency improvements. Underlying EBITDA margin increased by 4.4 percentage points to 22.5% (H1 2024: 18.1%) compared to the previous year. Free cash flow rose to EUR 93 million in the first half of the year (H1: EUR 36 million), nearly tripling compared to the same period last year. The strong capital structure enhances the company’s ability to continue investing in innovation and growth in the future.

Oliver Jakobi, CEO of Ottobock SE & Co. KGaA: “Our success in the first half of 2025 once again underlines that Ottobock is on a growth path, based on our innovation strength. We continue to invest in future technologies – from intelligent prosthetics and neurotechnological interfaces to exoskeletons. Our innovation pipeline is well filled, and, together with leading research partners, we are developing solutions that are redefining our market. Innovation will remain our key growth driver.” Dr. Arne Kreitz, CFO of Ottobock SE & Co. KGaA: “Ottobock is thriving and in excellent financial health. We have continued the dynamic, innovation-driven growth of recent years with significant increases in revenue and margin. This makes us very confident for the second half of the year and thus also for achieving our full-year targets.” In the first half of 2025, Ottobock launched four strategic key products – including the new Speedhand Solution in prosthetics, the next generation of the Exopulse Suit, and the active exoskeleton Volton. A strong R&D ratio in the product and component business, as well as strategic investments in start-ups like Phantom Neuro, BionicSkins, and Musclemetrix LLC, further supports innovation and the development of pioneering technologies. The field of human-machine interfaces, as a basis for the neural control of prostheses and orthoses, is also gaining importance.     Contact Media: Merle Florstedt     
Head of Corporate Communications & Company Spokesperson 
Phone: +49 151 441 616 25
Email: Merle.Florstedt@ottobock.de   Contact Investor Relations: Julia Hartmann     
VP Investor Relations 
Phone: +49 151 556 848 07
Email: julia.hartmann@ottobock.de
  About Ottobock Ottobock, a global MedTech champion, combines over 100 years of tradition with outstanding innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons. Ottobock develops innovative fitting solutions for people with limited mobility and is driving the digitalisation of the industry. Founded in Berlin in 1919, the company is active in over 140 countries with around 9,100 employees and operates the largest international patient care network with around 400 locations. Ottobock is shaping the future of Human Bionics with a strong R&D ratio in the products and components business and more than 2,500 patent applications. Ottobock’s mission of improving freedom of movement, quality of life and independence is deeply rooted in the company's DNA, as is its social commitment: Ottobock has been a partner and supporter of the Paralympics since 1988.